Mebendazole reduces vascular smooth muscle cell proliferation and neointimal formation following vascular injury in mice

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Wang, Jintao ^a   Wang, Hui ^a   Guo, Chiao ^a   Luo, Wei ^a   Lawler, Alyssa ^a   Reddy, Aswin ^a   Wang, Julia ^a   Sun, Eddy B ^a   Eitzman, Daniel T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEBENDAZOLE; PLACEBO;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTICLE; BLOOD VESSEL INJURY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FEMORAL ARTERY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROTUBULE; MOUSE; NEOINTIMA; NONHUMAN; VASCULAR SMOOTH MUSCLE; WILD TYPE; WOUND HEALING;

ANIMALS; APOPTOSIS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HYPERPLASIA; MALE; MEBENDAZOLE; MICE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; VASCULAR SYSTEM INJURIES;

EID: 84896325190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090146     Document Type: Article

References (24)

1. Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U (1997) Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 45: 837-846. (Pubitemid 27248799)
2. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801. (Pubitemid 38823766)
3. Schwartz SM, deBlois D, O'Brien ERM (1995) The intima. Soil for atherosclerosis and restenosis. Circ Res 77: 445-465.
4. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R (2002) Morphological predictors of restenosis after coronary stenting in humans. Circulation. 105(25): 2974-2980. (Pubitemid 34693829)
5. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, et al. (2010) Instent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 56: 1897-1907.
6. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, et al. (2007) Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA. 298: 1911-1924. (Pubitemid 350005235)
7. Laclette JP, Guerra G, Zetina C (1980) Inhibition of tubulin polymerization by mebendazole. Biochem Biophys Res Commun. 92: 417-423. (Pubitemid 10098582)
8. Gull K, Dawson PJ, Davis C, Byard EH (1987) Microtubules as target organelles for benzimidazole anthelmintic chemotherapy. Biochem Soc Trans. 15: 59-60.
9. Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, et al. (2004) Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation. 109: 487-493. (Pubitemid 38168511)
10. Vockel M, Pollok S, Breitenbach U, Ridderbusch I, Kreienkamp HJ, et al. (2011) Somatostatin inhibits cell migration and reduces cell counts of human keratinocytes and delays epidermal wound healing in an ex vivo wound model. PLoS One. 6: e19740. doi: 10.1371/journal.pone.0019740. accessed May 17, 2013.
11. Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, et al. (2000) A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 32: 2097-2104.
12. Doudican N, Rodriguez A, Osman I, Orlow SJ (2008) Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 61308-1315.
13. Levin MH, Weinstein RA, Axelrod JL, Schantz PM (1983) Severe, reversible neutropenia during high-dose mebendazole therapy for echinococcosis. JAMA. 249: 2929-2931. (Pubitemid 13096143)
14. Cañete R, Escobedo AA, Almirall P, González ME, Brito K, et al. (2009) Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. Trans R Soc Trop Med Hyg. 103: 437-442.
15. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, et al. (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther. 1: 1201-1209.
16. Pourgholami MH, Akhter J, Wang L, Lu Y, Morris DL (2005) Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol. 55: 425-432. (Pubitemid 40568971)
17. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA (2002) Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 8: 2963-2969. (Pubitemid 35025745)
18. Müller E, Akovbiantz A, Ammann RW, Bircher J, Eckert J, et al. (1982) Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology. 29: 236-239. (Pubitemid 13065517)
19. Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU (1994) Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology. 19: 735-742. (Pubitemid 24066907)
20. Epstein AJ, Polsky D, Yang F, Yang L, Groeneveld PW (2011) Coronary revascularization trends in the United States, 2001-2008. JAMA. 305: 1769-1776.
21. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, et al. (2010) Instent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 56: 1897-1907.
22. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, et al. (2007) Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 297: 159-168. (Pubitemid 46089732)
23. Geng DF, Liu M, Jin DM, Wu W, Deng J, et al. (2012) Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients. Cardiology. 122: 148-157. doi: 10.1159/000338812.
24. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, et al. (2011) Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stent implantation) trial. J Am Coll Cardiol. 57: 280-289.